Table 1: MiRNAs profiling studies in glioblastoma "ex vivo" specimens


Number of Human miRNAs analyzed Samples setting Methods Up-regulated miRNAs Down-regulated miRNAs References
245 9 fresh GBMs vs 9 ANBs Microarray -10b, -130a, -221, -125b-1, -125b-2, -9-2, -21, -25, -123 -128a, -181c, -181a, -181b [15]
180 3 fresh GBMs vs 8 NBs Microarray -21, -138, -347, -291-5', -135 -202 [24]
534 240 GBMs vs 10 NBs (data from TCGA) Microarray -15a, -15b, -16, -17-5p, -25, -92, -93, -106a, -106b, -320, -502, -532, -590, -660 -487a, -323, -329, -218 [28]
474 3 fresh GBMs vs 2 NBs Microarray -10b, -182, -10a, -183, 21, -148a, -503, -505, -451, -144, -542-5p, -542-3p, -26a, -142-3p, -199b, -15b, -550, -25, 9*, -92b, -142-5p, -27a, -23a, -486, -362, -532, -93, -106b, -223 None found [34]
756 26 fresh GBMs vs 13 AAs Microarray -16, -21, -22, -24, -34a, -126, -142-5p, -143, -146b-5p, -155, -193a-3p, -199a/b-3p, -335, 376c, -381, -451, -509-3-5p, -513a-5p, -552, -886-3p/5p -128, -219-2-3p [43]
127 3 fresh GBMs vs ANB Microarray -10b, -21, -183, -92b, -106b -302c , -379, -329, -134, -369-3p [44]
305 222 GBMs vs 10 NBs (data from TCGA) Microarray -20a, -106a, -17-5p, -148a, -146b, -200b, -193a -221, -222, -31 [49]
NS 261 GBMs vs 10 NBs (data from TCGA) Microarray -21, -10b, -210, -27a, -25, -15b, -23a, -92b, -106b, -92, -155, -93, -339, -494, -565, -130b, -34a, -16, -20a, -320, -106a, -19b, -100, -17-5p, -424 -124a, -139, -134, -7, -218, -338, -129, 2-19, -128b, -128a, -136, -410, -138, -29b, -29c, -491, -132, -379, -377, -149, -769-5p, -330, -323 [50]
1145 82 fresh GBMs vs 5 NBs Microarray -518b, -566 -181d, -524-5p, -1227 [55]
282 12 fresh GBMs and 12 fresh O vs 4 fresh NBs Microarray and qRT-PCR -21, -155, let-7f, let-7a, -16, -15b, -9, -210 -132, -128, -7, -330-3p, -139-5p, -124 [37]
8 10 fresh GBMs, 10 AAs, 8 LGAs, vs 4 NBs qRT-PCR -21, -221 -181b [25]
365 8 fresh GBMs vs 4 AAs qRT-PCR -15b, -21, -135b, -196a, -196b, -363 -105, -128b, -184, -302b, -302d, -367, -383, -504, -517c, -601 [32]
875 § 3 fresh GBMs vs 3 NBs NGS -10b, -96, -10b*, -182, -135a*, -21*, -21, -542-3p, -148a, -92b -433, -7-1*, -129*, -628-5p, -935, -218, -31, -876-3p, -1258, -132 [33]
157 4 fresh secondary GBMs vs LGGs qRT-PCR -9, -15a, -16, -17, -19a, -20a, -21, -25, -28, -130b, -140, -210 -184, -328 [40]
192 4 fresh GBMs, 4 AAs vs 4 NBs qRT-PCR -10b, -21, -155, -210 -7, -31, -107, -124, -124b, -129, -137, -138, -139, -187, -203, -218, -101, -128a, -132, -133a, -133b, -149, -153, -154*, -185, -29b, -323, -328, -330 [47]
Whole-genome small RNA sequencing (according to miRBASE v 16.0) 6 fresh GBMs vs 3 NBs NGS -10b*, -10b, -891a, -93, -196b, -21*, -320d, -217, -4448, -25, -660, -21, -320c, -296-3p, -92b, -10a, -92a, let-7i*, -148a* -124, -95, -132, -139-5p, -7, -543, let-7d, -323-3p, -128, -598, -103a, -103b, -139-3p, -487b, -873, -323b-3p, -1381*, -301b, -107, -411-3p, -124*, -342-3p, -379*, -212, let-7g, -153, -181d, -22, -889, -885-5p, -379, -138, let-7e, -218, -221, -136, -24, -4787-3p, -126, -548i, -382, -1270, -495, -2392, -1273d, -767-5p, -770-5p, -504, -490-3p [48]
>1000 35 FFPE GBMs: short-term vs long-term survivors Microarray miR-3163 -539, -1305, -1260, let-7a [63]
8 22 FFPE-dissected GBMs vs 6 NBs qRT-PCR -21, -125b -128a, -222, -221, -181b, -181c, -181a [65]
8 38 FFPE GBMs vs 6 NBs and 4 commercial RNAs qRT-PCR -196a, -196b, -21 -128a, -221, -195, -222, -181c [66]


Only miRNAs showed a fold change greater than or equal to two-fold, were considered. GBM: Glioblastoma, AA: Anaplastic Astrocytoma, NB: Normal Brain, ANB: Adjacent Normal Brain, LGA: Low Grade Astrocytoma, LGG: Low Grade Glioma, O: Oligodendroglioma, DA: Diffuse Astrocytoma, NS: Not Specified, NGS: Next Generation Sequencing, TGCA: The Cancer Genome Atlas (TCGA) Datasets, FFPE: Formalin-Fixed Paraffin-Embedded. In bold, miRNAs reported up- or down-regulated in at least 3 studies. § Only the most 10 up- or down-regulated miRNAs are reported, The authors considered a cut-off fold change ≥ 1.5.